Lower-dose transplant medicines to prevent graft-versus-host disease
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This early-phase study tests a lower dose of cyclophosphamide given after a stem cell transplant to prevent graft-versus-host disease (GVHD). It also uses sirolimus and mycophenolate to improve how well the donor immune system accepts the transplant, aiming to reduce side effects while keeping protection against GVHD.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a blood cancer that is an accepted type for this study (like AML, ALL, certain lymphomas, MDS, or related diseases) and be in a qualifying remission or disease status.
- You must be at least 18 and have a plan for an allogeneic (from another person) stem cell transplant using a suitable donor.
- Your health and organ function must meet minimum limits, including heart pumping ability, lung breathing tests, kidney function, and liver lab results.
- You must have a donor match option such as a 10/10 matched donor or a “half-matched” (haploidentical) donor.
- If you can become pregnant (or father a child), you must use highly effective birth control starting before treatment and continue for at least one year after transplant.
- You must be able and willing to sign informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This trial tests adding a drug called emapalumab to standard medications (cyclophosphamide, tacrolimus, mycophenolate mofetil) to prevent graft-versus-host disease in adults receiving a donor stem cell transplant. This approach aims to reduce complications after transplant.
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
This Phase 2 study tests ways to lower the risk of graft-versus-host disease (GVHD), a serious complication after an allogeneic stem cell transplant from a matched donor. It is for people with acute leukemia or MDS who are going to receive intensive conditioning therapy, aiming to improve safety while keeping the transplant effective.
This study tests whether a lower dose of a drug used after bone marrow transplant can reduce side effects while still preventing graft-versus-host disease (a condition where donor cells attack the patient's body). It is for older patients or those who are not healthy enough for a standard, stronger conditioning regimen.
This study tests a way to lower the chance of graft-versus-host disease (a common side effect of stem cell transplants) by removing certain immune cells from the donor's stem cells before they are given to you. It is for older patients with acute leukemia or MDS who are getting a transplant.
Hear when a new Peripheral Blood Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.